Blincyto blinatumomab: Phase II data

The single-arm, international, pivotal Phase II BLAST trial in 113 evaluable precursor Beta cell ALL patients with MRD showed that once-daily 15 µg/m 2 IV

Read the full 255 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE